Revive Therapeutics Announces Proposed Shares for Debt Settlement Aug 19, 2026 02:35PM
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Aug 19, 2026 08:40AM
Revive Therapeutics Reports Grant of Options Aug 14, 2026 06:50PM
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Aug 12, 2026 07:55AM
Revive Therapeutics closes first tranche of private placement Jul 15, 2026 06:40PM


Jul 15, 2026 06:40PM Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Jun 26, 2026 04:16PM Revive Therapeutics proposes $1M private placement
Jun 26, 2026 04:15PM Revive Therapeutics Announces Proposed Private Placement
May 20, 2026 07:45AM Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Mar 11, 2026 07:30AM Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Mar 3, 2025 08:00AM DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis